In contrast, ASHRA clearly detected the intermediate HR activity of BRCA1-R1699Q and -V1736A (Fig. 2E), which was associated with intermediate sensitivity to olaparib (Fig. 2F and G) and cancer risk (27–30). This evidence concerns the gene BRCA1 and cancer.